E-CEL UVEC Cell Injection Treatment of Perianal Fistulas
Part of paid clinical trials in New York, New York.
- Sponsor
- Angiocrine Bioscience
- Study ID
- NCT07557134
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cryptoglandular Perianal Fistula
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- E-CEL UVEC Cells — BIOLOGICALIP treatment involves percutaneous injections along the entire fistula tract and submucosal injections into the internal tract opening using anoscopic visualization
Study Details
The purpose of this study is to determine if experimental therapy (E-CEL UVEC Cells), a very minimally invasive procedure, can treat patients with perianal fistulas.
Key Dates
- Start date
- May 31, 2027
- Status verified
- Apr 2026
- Primary completion
- Sep 30, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 78 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A, Active
- No Intervention: Arm B, No Treatment Concurrent Control, eligible for crossover
Primary Outcome Measure
Clinical response (CR) rate at Week 12, comparing Arm A to Arm B in parallel. [ Time Frame: Week 12 ]
Central Contacts
- John R Jaskowiak877-784-8496
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| New York Presbyterian/Weill Cornell Medical Center | New York | New York | 10028 | Jeffrey W Milsom, MD, FACS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site